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Introduction 
Systemic lupus erythematosus (SLE) 
is a complex, chronic, multi-system 
autoimmune disease which varies in 
prevalence and incidence depending on 
ethnicity and is diagnosed about nine 
times more frequently in women than 
men (1, 2). In the UK approximately 
25,000 people have a diagnosis of SLE (3). 
The disease is highly heterogenous in that 
it varies in manifestations and severity 
between individuals. Disfigurement 
caused by the involvement of skin 
and joints (4) can affect the patient’s 
perception of body image and sexuality 
(5), can have an impact on emotional 
health (6) and overall quality of life (7). 
Involvement of the musculoskeletal 
system is common during the clinical 
course of SLE in up to 95% of patients, 
with joint pain being the first presenting 
symptom in up to 50% of cases (8). The 
extra articular manifestations of SLE 
include soft tissue pathology such as 
capsular swelling, synovial hypertrophy 
(thickening of joint lining) and 
tenosynovitis (9) which can lead to tendon 
rupture (10) or tendon contracture (11). 
Tendons are the force transmitting units 
of the musculoskeletal system, but due 
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to their low metabolic rate and slow 
healing, injury can result in considerable 
morbidity and prolonged disability. In 
relation to the symptoms associated with 
muscle involvement, these can range in 
severity from mild aches in up to 80% of 
cases to painful inflammatory myositis in 
up to 11% of cases (8). 
An additional factor that has the 
potential to contribute to a lower health 
related quality of life (HRQoL) in this 
patient group is vascular involvement. 
Vascular involvement can be either a 
direct complication of SLE or develop 
as co-morbidity. Vascular involvement 
represents the most frequent cause of 
death in patients with SLE (12). Mathieu 
et al (13) identified that abnormal 
vascular reactivity and coagulopathy 
both contribute to an increased risk of 
atheroma and therefore recommend 
careful monitoring for any vascular 
change with the aim of preventing tissue 
necrosis and ultimately amputation or 
death. Thus regular review of lower limb 
vascular health may be a key factor in 
maintaining health related quality of life. 
A recent narrative review (14) identified 
that there are some indications that SLE 
affects foot and lower limb morbidity and 
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Abstract
Systemic lupus erythematosus (SLE) can manifest in the lower limb with joint and muscle pains and in severe cases, 
disorganisation of the joints and tendon rupture. In the foot and lower limb, Raynaud’s phenomenon and other circulatory 
problems have been reported and may be associated with loss of sensation or altered pain perception. Associated with 
impaired peripheral neurovascular function are changes in tissue viability leading to either callus formation or thinning 
of the skin and ulceration. Many medications used to manage SLE can impact on the person’s resistance to infections 
and consequently fungal, bacterial or viral infections can spread rapidly and persist. Although there is some evidence for 
this range of problems occurring in the foot, it is not known how prevalent they are, what interaction there is between 
problems, and how these impact upon a person’s health related quality of life (HRQoL). Thus, the main aim of this study 
is to determine the self-reported foot and lower limb problems experienced by people with SLE. A secondary aim is to 
explore the impact that the identified foot and lower complications may have upon patients with SLE. It is anticipated that 
this research will highlight areas of potential health care need and thus can be used to inform recommendations about foot 
health care for this patient group and the focus of future research.
An investigation into self-reported foot and 
lower limb problems associated with systemic 
lupus erythematosus (SLE): A research proposal
Lindsey Cherry, Christopher J. Edwards, Lee-Suan Teh, Anita Williams
2Working Papers in the Health Sciences 1:7 Spring ISSN 2051-6266 / 20140033
that these have the potential to impact 
upon HRQoL. However, the scale of these 
problems is unclear and little research 
in this area has been completed to date. 
It could be speculated that the altered 
peripheral neurovascular and tissue 
health experienced by patient with SLE 
renders their feet particularly susceptible 
to pain, deformity, poor function, 
ulceration or infection. Further, the 
provision of foot health care for patients 
with SLE is inconsistent across the UK, and 
examination of the feet may be omitted 
from routine clinical examination (15). As 
such, the impact of such foot and lower 
limb problems, or the care thereof, upon 
HRQoL in this patient group also remains 
unclear to date. 
One of the obstacles to achieving 
consistent and high quality foot and 
lower limb health review is the lack of 
a ‘gold standard’ model for assessment 
in this patient group. Arguably, early 
identification of foot and lower limb 
problems, would allow appropriate 
interventions to be provided in a 
‘window of opportunity’ which may 
be similar to that experienced by 
patients with rheumatoid arthritis (16). 
However, before ‘gold standard’ foot 
assessment can be achieved, there 
is a need to determine the specific 
problems experienced by patients with 
SLE, how these may interact, and how 
they may affect HRQoL. An improved 
understanding of the range and impact of 
foot or lower limb problems experienced 
by patients with SLE could be used to 
inform recommendations regarding the 
type, frequency and nature of foot health 
care required to maintain HRQoL and 
provide the information to develop a 
future research strategy in this area.
Research aim and objectives 
The main aim of this study is to determine 
the self-reported foot and lower limb 
problems experienced by people with 
systemic lupus erythematosus. A 
secondary aim is to explore the impact 
that the identified foot and lower limb 
problems may have upon patients with 
SLE. The study objectives are therefore 
to:
1. Develop a survey questionnaire 
through a focus group of purposively 
sampled participants
2. Use the developed survey to determine 
the foot and lower limb problems 
experienced by patients with SLE .
3. Explore the impact of reported 
problems upon health related quality of 
life through a series of conversational 
style patient interviews 
4. Use the above objectives to inform 
recommendations regarding the type, 
frequency and nature of foot health 
care required to maintain health related 
quality of life for patients with SLE
Proposed methodology
Study design 
The study utilises a mixed method design 
with quantitative survey data (stage one) 
and qualitative patient interview (stage 
two). Participants will be prospectively, 
purposively selected for both stages. 
Research ethical approval for the study 
has been sought and all activity will 
be conducted in accordance with the 
declaration of Helsinki guidelines for 
research practice (1975).
Patient engagement in the study 
advisory group
Two patients with SLE will be identified 
from a rheumatology outpatient clinic 
as volunteers to join the study advisory 
group. A participant information sheet 
will be provided prior to their inclusion in 
the advisory group and consent obtained. 
The advisory group will comprise the 2 
patients, the principal investigator, the 
co-investigator, the research associate, 
and two consultant rheumatologists. 
Patient advisors will contribute 
feedback in relation to questionnaire 
design, participant recruitment and 
involvement, survey completion rates, 
potential interview questions, and results 
dissemination. 
STAGE ONE: Survey of patient 
experience
Survey development 
Survey development will take the form of 
a focus group with the aim of generating 
an item pool to develop the questionnaire. 
The focus group will review existing 
literature on foot problems associated 
with Lupus, information from other 
foot health related questionnaires such 
as The Manchester pain and disability 
questionnaire (17), a SLE specific 
health related quality of life measure 
(‘LupusQoL’) (18, 19), a disease activity 
measure (‘BILAG-2004’) (19), a damage 
measure (‘SLICC-ACR-Damage Index’) 
(20) and consider the experiences of 
patients and practitioners involved 
in foot and lower limb health care. 
From this consensus approach to item 
generation, the survey questionnaire 
will be formulated based on the agreed 
themes, categories, question format and 
overall structure (21). The survey will 
be checked for face and content validity 
prior to cognitive debriefing in order to 
ensure usability, understanding of the 
process of completing the survey and 
understanding of the questions, prior to 
its launch (21). 
Survey sample size
Audit data from the proposed clinical 
sites suggests that approximately 500 
patients may be eligible for participation; 
given a 50% response rate, a sample 
size of approximately 250 participants is 
feasible. This sample size and response 
rate is in-line with similar surveys of this 
kind. 
Survey completion 
Patients will be recruited from 
University Hospital Southampton NHS 
Foundation Trust, Southampton; The 
Royal Bournemouth and Christchurch 
hospitals NHS Foundation Trust, 
Bournemouth; Royal Blackburn Hospital, 
Lancashire; Chapel Allerton Hospital, 
Leeds; Manchester Royal Infirmary and 
Salford Royal Hospitals Foundation Trust, 
Salford. Patients will be invited by their 
consultant/specialist nurse to consider 
completing the questionnaire. Posters will 
be displayed in the waiting areas of each 
respective clinic to publicise the survey 
and provide an overview of the aims and 
objectives of the study. Patients will be 
reassured by their consultant/specialist 
nurse that a decision to take part in the 
survey or not, will have no impact on 
their ongoing care provision. Patients 
will be included who are: diagnosed with 
definite SLE according to ACR criteria (22, 
23), aged 18 years or older and are able 
and willing to participate. 
STAGE TWO: Patient interviews
 
Participant interviews 
Potential participants for this stage 
(n=12) will be identified as a purposive 
sample by their consultant or specialist 
nurse. The sample size is pragmatically 
derived and in accordance with similar 
published work of this kind. Patients will 
be included who: are diagnosed with 
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definite SLE according to ACR criteria (22, 
23), have self-reported foot or lower limb 
problems, are aged 18 years or above and 
are willing and able to participate in an 
interview. Conversational style interviews 
are proposed using an underpinning 
interpretivistic, phenomenological 
approach to both data collection and 
analysis (24). The interviews will be 
digitally recorded and complemented 
by field notes. It is intended for the 
researcher to only ask trigger questions 
for all participants and then dependent 
on responses,  further questions will be 
asked (24). An opening question will be 
used for all participants; “tell me about 
your experiences of having lower limb 
and foot problems?”
Data Analysis
Survey Data Analysis 
All participants completing the survey 
will be identified by the location of the 
centre and participant project number 
and all forms will be identified by the 
number only. Once all data forms 
collected from questionnaire stage of 
the study have been entered into SPSS 
the original forms will be destroyed. The 
descriptive data obtained from the survey 
will be analysed using SPSS software. 
Continuous data will be summarised 
by means (±standard deviations), 
frequency counts and percentages. The 
Student’s t-test, analysis of variance 
(with appropriate post hoc tests), Chi 
square and correlation coefficients will 
be used to test for significant associations 
between lower limb/foot problems and 
reported symptoms; disease duration and 
reported foot problems, with significance 
set at the p<0.05% confidence level.  All 
participants will be described in terms of 
gender, age, disease duration and current 
medical management.
Interview Data Analysis 
Data will be transcribed verbatim and 
analysed using a thematic framework 
approach (25) by the research team.. 
Themes that have emerged from the 
analysis of the qualitative data will be 
supported with exemplars from the 
transcripts in order to support the 
truthfulness of the data and illuminate 
the themes. Also the results will be 
analysed by a second researcher in order 
to add to the credibility of the analyses. 
Further the results will be viewed by the 
participants to confirm a true reflection 
of what they meant and to ensure correct 
interpretation of the dialogue. 
The results of both stages will be 
discussed by the advisory group and a 
consensus achieved on the conclusions, 
recommendations for practice and for 
future research.
Intended outcomes and benefits 
for clinical practice 
It is anticipated that this research project 
will lead to new knowledge about the 
type, frequency and impact that foot 
and lower limb problems may have 
upon HRQoL for patients with systemic 
lupus erythematosus (SLE). An improved 
understanding of the range and impact of 
foot or lower limb problems experienced 
by patients with SLE could be used to 
inform recommendations regarding the 
frequency and nature of foot health care 
required to maintain HRQoL. Specifically, 
the results of the study will be used to:
• Influence the consultation practice 
of health professionals involved in the 
management of patients with SLE. This 
will be implemented through clinical 
forums such as the NW Rheumatology 
Club meetings, British health 
Professionals in Rheumatology, Arthritis 
Research UK, and through the Arthritis 
and Musculoskeletal Alliance standards 
committee.
• Develop guidelines for the assessment 
and management of foot problems 
through the Podiatric Rheumatology 
Clinical Effectiveness Group network
• Influence the undergraduate and 
postgraduate training of practitioners 
involved in the assessment and provision 
of foot care to patients with SLE
Findings from this study will also be 
disseminated to patients via various 
patient groups (e.g. Lupus UK) and as 
advised by the study advisory group. 
Overall, it is anticipated that the findings 
of this study will inform clinical guidelines 
in this area of practice thereby potentially 
improving the consistency and quality of 
foot health care for this patient group. 
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